Rapid Micro Biosystems Q3 commercial revenue $6.3M (+27%); reaffirms FY21 outlook

RAPID MICRO BIOSYSTEMS, INC.

2021-Q3 EPS reported -$5.14 revenue$18,024,000

Commercial revenue $6.3M (+27% YoY); recurring commercial revenue $2.2M (+154% YoY).
Net loss of $25.0M includes $8.2M warrant fair-value adjustment and $3.1M debt-repayment charge.
Cash $220M, no debt; repaid $28.7M term debt in September using IPO proceeds.
Placed 10 Growth Direct systems and completed validation of 5 customer systems in Q3.
Reaffirms FY2021 commercial revenue outlook of at least $24M, representing ≥70% YoY growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.